Home  >  News
Eppen_Cent_Feb24
you can get e-magazine links on WhatsApp. Click here
Diagnostics + Font Resize -

Amedisys offers molecular testing for rapid and accurate infection diagnosis

Baton Rouge, Louisiana
Saturday, February 10, 2024, 16:00 Hrs  [IST]

Amedisys, Inc., a leading provider of home health, hospice and high-acuity care in the home, is now offering advanced molecular testing to its care centers nationwide. This innovative collaboration with Patient Choice Laboratories utilizes molecular testing for the swift and precise identification of pathogens in urine, respiratory and wound infections. By leveraging the latest in diagnostic technology, Amedisys aims to improve the quality of infection testing, ultimately facilitating better patient care and outcomes.

Advanced molecular testing revolutionizes the diagnosis and management of infections, as it delivers rapid and precise results, ultimately enabling quicker initiation of appropriate treatment interventions. With improved accuracy, sensitivity and specificity, molecular testing significantly enhances the ability to identify infectious pathogens, supporting timely and targeted care strategies.

“We are excited to integrate molecular testing capabilities into our infection diagnosis protocols,” states Cyndi Shook, senior vice president of clinical operations at Amedisys. “This advancement represents a significant step in our ongoing commitment to providing the highest quality of care to our patients. By leveraging the latest in diagnostic technology, we can further enhance the accuracy and speed of infection testing, allowing us to tailor treatment plans to the individual needs of each patient.”

“Patients Choice Laboratories is excited to partner with Amedisys, one of the leaders in the home health industry, in an effort to improve outcomes for patients suffering from infectious diseases,” said Brad Moss, president at Patients Choice Laboratories. “Our automated pre-analytical, analytical and post-analytical processes in molecular technologies provide the necessary clinical decision support so that treatments are targeted and successful.”

“According to the CDC, more than one-third of deaths of people over the age of 65 are caused by infectious diseases, thus making turnaround time critical so that the most appropriate treatment(s) are deployed in the early stages of infection,” added Thomas Payne, chief operations officer at Patients Choice Laboratories. “Molecular testing provides the speed and accuracy needed to detect pathogens across our entire infectious disease platform.”

“Our partnership with Patient Choice Laboratories aligns seamlessly with our dedication to delivering exceptional care and optimizing patient outcomes,” added Barbara Andazola, vice president of clinical practice, strategy and programs at Amedisys. “By incorporating molecular testing into our infection diagnosis protocols, we are empowering our care teams to provide more accurate and effective treatments, ultimately reducing the impact of infections and preventing related hospitalizations.”

Amedisys has implemented comprehensive protocols and training to ensure seamless integration of molecular testing into its care centers. The rollout of this innovative approach to infection diagnosis underscores the organization’s commitment to staying at the forefront of healthcare advancements and technology, ultimately providing its patients with the highest standard of care and support.

Amedisys, Inc. is a leading healthcare at home company delivering personalized home health, hospice and high-acuity care services. Amedisys is focused on delivering the care that is best for our patients, whether that is inpatient hospital, palliative, and skilled nursing facility (SNF) care in their homes; home-based recovery and rehabilitation after an operation or injury; care focused on empowering them to manage a chronic disease; or hospice care at the end of life.


Patients Choice Laboratories (PCL), a CLIA certified and CAP accredited laboratory based in Indianapolis, Indiana, is a leading provider of comprehensive laboratory testing throughout the United States.

 




*POST YOUR COMMENT
Comments
* Name :     
* Email :    
  Website :  
   
     
 
CEI_CPT_CLI_150x60
Pharma_India_Expo24
India Lab Expo
Copyright © 2023 Saffron Media Pvt. Ltd |